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ABSTRACT
Background: Although recent genome-wide
association studies have identified several genetic
variants contributing to the complex aetiology of
multiple sclerosis (MS), expression and functional
studies are required to further understand its
molecular basis.
Objectives: To identify genes and pathways with
differential expression in MS.
Design: The authors conducted a systematic review of
seven microarray studies, in which expression in
immune cells was compared between MS patients and
controls. These studies include a previously
unpublished study, which is described here in detail.
Results and conclusion: Although in general the
overlap between studies was poor, 229 genes were
found to be differentially expressed in MS in at least
two studies, of which 11 were in three studies and
HSPA1A in four studies. After excluding the authors’
unpublished experiment which may have been affected
by certain confounding factors and inclusion of treated
subjects, 135 genes were identified in at least two
studies. The differentially expressed genes were
significantly associated with several immunological
pathways, including interleukin (IL)-4, IL-6, IL-17 and
glucocorticoid receptor signalling pathways. 15 of the
229 loci have shown some association with MS in
published genome-wide association studies
(p<0.0001), including three loci with confirmed MS
risk variants.
INTRODUCTION
The aetiology of multiple sclerosis (MS) is
complex and involves both genetic suscepti-
bility and environmental factors. However,
apart from the widely replicated association
with human leukocyte antigen (HLA)-
DRB1*1501, genetic risk factors have
remained unknown until genome-wide asso-
ciation studies (GWAS), which have recently
led to identification of common MS risk
variants in over a dozen loci.1e6 Although
further fine-mapping and functional studies
are required in order to verify the causal
variants and genes, a strong presence of
immunological genes in these loci is evident.
Expression and functional studies in immune
cells can therefore elucidate the molecular
mechanisms behind MS. Indeed, a number
of studies have been conducted where
genome-wide expression profiles in periph-
eral immune cells were compared between
MS patients and unaffected controls.
Together, these studies have reported a large
number of genes with differential expression
in MS. However, given that most of these
studies have been conducted in small
samples without replication, it is likely that
many of the findings are false positives.
Approaches are therefore needed to increase
the probability of detecting the true signals
from the vast number of reported genes. In
order to extract the genes which are more
likely to be true positives, we systematically
reviewed results from seven microarray
studies in MS, including our previously
unpublished study. First, we identified genes
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ARTICLE SUMMARY
Article focus
- To identify genes showing differential expression
in multiple sclerosis through genome-wide
expression profiling in peripheral blood mono-
nuclear cells.
- To conduct a systematic review of genome-wide
expression studies in multiple sclerosis in order
to identify the most frequently reported genes.
- To identify pathways associated with genes most
frequently reported as differentially expressed in
multiple sclerosis.
Key messages
- The vast majority of all genes reported as
differentially expressed were only identified in
a single study.
- However, 229 genes were reported as differen-
tially expressed in MS to the same direction in at
least two of the seven studies reviewed, 12 genes
of which were in at least three studies.
- After excluding our unpublished experiment.
which may have been affected by confounding
factors and inclusion of treated subjects, 135
genes were identified in at least two studies.
- The differentially expressed genes were signifi-
cantly associated with several immunological
pathways, including the IL-4, IL-6, IL-17 and
glucocorticoid receptor signalling pathways.
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which had been found to be differentially expressed in
MS to the same direction in at least two studies. In order
to further examine the potential role of these most
frequently reported genes, they were analysed using
pathway tools. Finally, we searched these genes for
evidence of association by making comparisons with top
results from recent MS GWAS.
MATERIALS AND METHODS
Samples in the Finnish microarray experiment
Twelve female patients fulfilling Poser’s criteria for
clinically definite MS were recruited through the Seina¨-
joki Central Hospital. Fifteen healthy unrelated female
controls were obtained from the Finnish Twin Study on
Ageing (FITSA). The mean age was 54.2 in patients and
71.6 in controls. One patient was receiving cortisone
treatment, two patients received b interferon, and one
patient was being treated with both b interferon and
cortisone at the time of sample collection. All subjects
had provided their informed consent. Peripheral blood
mononuclear cells (PBMCs) were isolated from whole
blood using BD Vacutainer CPT Cell Preparation Tubes
(Becton, Dickinson and Company, Franklin Lakes, New
Jersy), and cells were disrupted and RNA extracted with
TRIzol Reagent (Invitrogen, Carlsbad, California). RNA
was then purified using Rneasy Mini Kit (Qiagen,
Hilden, Germany), and the sample quality was examined
using BioAnalyzer (Agilent, Santa Clara, California). The
study was approved by the Committee on Ethics of the
Central Hospital of Central Finland and by the Helsinki
University Hospital Ethical Committee of Ophthal-
mology, Otorhinolaryngology, Neurology and Neuro-
surgery (permit 192/E9/02) for FITSA and patient
samples, respectively.
Sample processing and microarrays
Eleven patient samples were prepared for hybridisation
on the Affymetrix GeneChip Human Genome U133 Plus
2.0 Array (Affymetrix, Santa Clara, California) according
to the manufacturer’s recommendations in our labora-
tory. In addition, one patient sample and technical
replicates from two of the 11 patient samples were
prepared according to the manufacturer’s recommen-
dations at the Helsinki Biomedicum Biochip Centre
(BBC), where 15 control samples had been previously
prepared. In brief, 1e2 mg of total RNA was converted to
biotin-labelled cRNA using the Affymetrix HT One-Cycle
cDNA Synthesis Kit and the HT IVT Labelling Kit.
Fifteen micrograms of cRNA was then fragmented and
hybridised for 16 h at 458C, washed in Affymetrix
Fluidics Station 450 and scanned with Affymetrix Gene-
Chip Scanner 3000. Hybridisation, washing, staining and
scanning were conducted using the same instruments
for all samples. All arrays had a present call percentage
>40 (42e47) and average background signal <50
(36e44).
Microarray data analysis
Raw intensity data files were imported to GeneSpring 7.3
(Agilent Technologies, Santa Clara, California) and GC
Robust Multi-array Average (GC-RMA) normalised. We
then applied filtering steps in order to exclude probe
sets with low signal intensity and probe sets potentially
affected by differences between our laboratory and the
BBC. First, we excluded all probe sets with a GC-RMA
normalised signal <50 in at least 20 of the 27 arrays
(N¼35 203). Second, we excluded probe sets where the
technical replicates showed a >1.4-fold difference in
both replicate pairs (N¼1668). Finally, we excluded
probe sets where the signal in all three MS arrays
prepared at the BBC ranked among the four lowest or
four highest among the MS arrays (N¼2469), after which
15 273 probe sets remained for analyses. After filtering,
we discarded the two replicate arrays prepared in our
laboratory and used only the replicates prepared at the
BBC for final analyses, which thereby included 12 MS
arrays and 15 control arrays. In order to identify genes
with differential expression in MS, we first applied the
fold-change filter in GeneSpring 7.3 using 1.5 as
threshold. For probe sets showing a 6$1.5-fold differ-
ence in mean expression between MS patients
and controls, we further determined non-parametric
ManneWhitney sum rank test p values with Benjami-
nieHochberg correction for multiple testing. Probe
sets with corrected a p value of #0.05 were considered to
be differentially expressed. In order to annotate these
probe sets, we compared the gene symbol obtained
from GeneSpring 7.3 in October 2008 with the
NetAffx annotation in December 2010 for each probe
set (http://www.affymetrix.com/analysis/index.affx). If
these were different, we first checked whether these were
ARTICLE SUMMARY
Strengths and limitations of this study
- This is the first systematic review of genome-wide expression
studies conducted in peripheral immune cells in multiple
sclerosis.
- Strict criteria were applied for inclusion of studies, and clearly
underpowered studies with fewer than 10 cases or controls
were excluded.
- Many of the genes we found to be reported by at least two
studies have interesting immunological functions and can be
considered promising candidates for further studies.
- However, the studies included should not be considered
directly comparable owing to differences in samples, platforms
and analyses methods used. In addition, the majority of these
studies are small and should be viewed with some caution.
- All studies were conducted in relatively heterogeneous cell
populations, and some of the findings could therefore be
explained by differences in numbers of different cell popula-
tions rather than differential transcriptional activity in MS.
- Finally, our previously unpublished microarray study may have
been affected by differences between the labs where the patient
and controls samples were prepared for arrays, as well as by
the higher mean age of controls. Our study also included four
patients who had received immunomodulatory treatment at the
time of sample collection.
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alternative identifiers for the same gene. If not, we
obtained the probe set nucleotide sequences from
NetAffx and performed a Blat search in UCSC Genome
Browser (hg19) to identify the correct target gene
(http://genome.ucsc.edu/cgi-bin/hgGateway). Probe
sets which recognise only intronic sequences or map to
several loci were excluded from the list of differentially
expressed probe sets. The Gene Expression Omnibus
(GEO) accession number for the microarray dataset is
GSE21942 (http://www.ncbi.nlm.nih.gov/geo/).
Pathway analysis
Pathway analyses were conducted using the Core Analysis
option in the Ingenuity Pathway Analysis software
(Ingenuity Systems, Redwood City, California). This
option identifies canonical pathways associated with
a given list of genes by calculating the Fisher exact test p
value for the probability that association between this set
of genes and a canonical pathway is explained by chance
alone. In order to account for the fact that our input lists
of genes were enriched for immunological genes and
would therefore show association with immune-related
pathways if compared with all genes, we restricted the
analyses to genes expressed in immune cells by applying
the Tissues & Cell lines filter in the analysis settings.
Systematic review of microarray studies in MS
We searched PubMed with keywords ‘multiple sclerosis
microarray’ in November 2010 and obtained 156
records. These were complemented with two additional
recent studies and studies identified through a review
article.7e9 Based on title, abstract and, if required, full
text, we first identified all studies which had been
conducted in peripheral immunological cells using
a microarray platform and compared expression profiles
between MS patients and unaffected controls. This led to
the exclusion of 144 studies, which were not MS-related
expression studies or investigated effects of MS treat-
ments, were conducted in animal models for MS, or were
performed in MS brain biopsies rather than immune
cells. We then reviewed the remaining studies in further
detail and excluded six studies with fewer than 10 MS
patients and/or controls, a study which did not identify
any differentially expressed genes, a study where only
genes involved in T-cell mediated cytotoxicity were
included in the analyses and a study where the list of
identified genes was not available in the publication or
upon contact with the corresponding author. The stages
of the selection process are depicted as a flow chart in
figure 1. Of the remaining eight studies which are listed
in table 1, only six were independent, because the two
studies by Satoh et al15 16 and the studies by Achiron
et al10 and Mandel et al13 had been conducted in the
same set of patients and were from hereon considered to
be single studies. After including our own unpublished
experiment, we therefore had seven independent studies
for the analysis. For each study, we listed all genes which
had been reported to be differentially expressed in MS
patients in comparison with healthy controls, and
recorded whether their expression in MS was increased
or decreased. The studies by Achiron et al10 and Mandel
et al13 listed only a selected subset of the identified
differentially expressed genes.10 13 The corresponding
author was contacted in order to obtain the full lists of
differentially expressed genes, but we received no reply,
and we therefore only included the reported genes. All
gene symbols were mapped to the Human Gene
Nomenclature gene symbols, and genes that were not
unambiguously linked to a single gene symbol using the
information available were excluded.
RESULTS
The previously unpublished microarray screen identifies 692
probe sets with differential expression in MS
We first analysed the data from our previously unpub-
lished Finnish microarray screen and identified 692
probe sets, which showed a $1.5-fold difference in mean
expression between 12 MS patients and 15 controls
together with a non-parametric ManneWhitney sum
rank test p value of #0.05 after BenjaminieHochberg
correction (supplementary table 1). Three hundred and
one probe sets showed increased expression, and 391
decreased expression in MS. Pathway analysis revealed
that the differentially expressed genes were strongly
Figure 1 Flow chart showing stages in selecting studies for
systematic review. MS, multiple sclerosis.
Kemppinen AK, Kaprio J, Palotie A, et al. BMJ Open 2011;1:e000053. doi:10.1136/bmjopen-2011-000053 3
Systematic review of genome-wide expression studies in multiple sclerosis
 group.bmj.com on January 10, 2013 - Published by bmjopen.bmj.comDownloaded from 
T
a
b
le
1
D
e
s
c
ri
p
ti
o
n
o
f
p
re
v
io
u
s
m
ic
ro
a
rr
a
y
e
x
p
re
s
s
io
n
s
tu
d
ie
s
in
c
lu
d
e
d
in
th
e
s
y
s
te
m
a
ti
c
re
v
ie
w
C
e
ll
s
P
la
tf
o
rm
N
o
o
f
c
a
s
e
s
(f
e
m
a
le
s
/
m
a
le
s
)
N
o
o
f
c
o
n
tr
o
ls
(f
e
m
a
le
s
/m
a
le
s
)
M
e
a
n
a
g
e
(c
a
s
e
s
/
c
o
n
tr
o
ls
)
N
o
o
f
re
p
o
rt
e
d
d
if
fe
re
n
ti
a
ll
y
e
x
p
re
s
s
e
d
g
e
n
e
s
w
it
h
a
H
u
m
a
n
G
e
n
e
N
o
m
e
n
c
la
tu
re
s
y
m
b
o
l
O
ri
g
in
a
l
p
u
b
li
c
a
ti
o
n
P
B
M
C
U
9
5
A
v
2
a
rr
a
y
(A
ff
y
m
e
tr
ix
,
C
a
lif
o
rn
ia
).
R
e
p
re
s
e
n
ts
a
p
p
ro
x
im
a
te
ly
1
0
0
0
0
g
e
n
e
s
.
2
6
(2
0
/6
)
1
8
(1
6
/2
)
4
1
/3
9
.6
3
4
A
c
h
ir
o
n
e
t
a
l1
0
W
h
o
le
b
lo
o
d
1
0
.5
K
P
e
te
r
M
a
c
C
a
llu
m
a
rr
a
y
(T
h
e
P
e
te
r
M
a
c
C
a
llu
m
C
a
n
c
e
r
In
s
ti
tu
te
,
A
u
s
tr
a
lia
).
R
e
p
re
s
e
n
ts
9
3
8
1
u
n
iq
u
e
c
D
N
A
s
.
2
0
(1
1
/9
)
P
o
o
le
d
s
a
m
p
le
(2
0
/0
);
fi
v
e
in
d
iv
id
u
a
l
s
a
m
p
le
s
(0
/5
)
N
o
t
p
ro
v
id
e
d
(r
a
n
g
e
3
0
e
6
6
in
M
S
,
2
0
e
5
5
in
c
o
n
tr
o
ls
)
2
2
1
7
A
rt
h
u
r
e
t
a
l1
1
P
B
M
C
c
D
N
A
a
rr
a
y
s
w
it
h
6
5
0
0
o
r
7
5
0
0
c
lo
n
e
s
w
it
h
p
a
rt
ia
l
o
v
e
rl
a
p
2
4
(1
5
/9
)
1
9
(5
/1
4
)
4
2
/3
7
.5
(a
g
e
fo
r
fo
u
r
c
o
n
tr
o
ls
u
n
k
n
o
w
n
)
1
0
4
B
o
m
p
re
z
z
i
e
t
a
l1
2
W
h
o
le
b
lo
o
d
H
T
-1
2
a
rr
a
y
(I
llu
m
in
a
,
C
a
lif
o
rn
ia
).
R
e
p
re
s
e
n
ts
4
8
8
0
4
tr
a
n
s
c
ri
p
ts
.
9
9
(6
6
/3
3
)
4
5
(2
9
/1
6
)
5
4
/4
8
.5
7
7
9
G
a
n
d
h
i
e
t
a
l9
P
B
M
C
U
9
5
A
v
2
a
rr
a
y
(A
ff
y
m
e
tr
ix
,
C
a
lif
o
rn
ia
).
R
e
p
re
s
e
n
ts
a
p
p
ro
x
im
a
te
ly
1
0
0
0
0
g
e
n
e
s
.
1
3
(9
/4
)
5
(4
/1
)
s
y
s
te
m
a
ti
c
lu
p
u
s
e
ry
th
e
m
a
to
s
u
s
(S
L
E
),
1
0
h
e
a
lt
h
y
c
o
n
tr
o
ls
(1
6
/2
)
4
0
.7
/4
2
.8
(S
L
E
)/
3
9
.6
7
8
M
a
n
d
e
l
e
t
a
l1
3
P
B
M
C
(m
o
n
o
c
y
te
s
d
e
p
le
te
d
)
G
e
n
e
F
ilt
e
rs
G
F
2
1
1
D
N
A
a
rr
a
y
(R
e
s
e
a
rc
h
G
e
n
e
ti
c
s
,
A
la
b
a
m
a
).
R
e
p
re
s
e
n
ts
5
1
8
4
g
e
n
e
s
.
1
5
(1
1
/4
)
1
5
(g
e
n
d
e
r
m
a
tc
h
e
d
to
c
a
s
e
s
,
b
u
t
n
u
m
b
e
rs
n
o
t
a
v
a
ila
b
le
)
4
2
.1
/4
1
.7
2
8
R
a
m
a
n
a
th
a
n
e
t
a
l1
4
T
c
e
lls
,
n
o
n
-T
c
e
lls
A
c
u
s
to
m
a
rr
a
y
w
it
h
1
2
5
8
c
D
N
A
s
(H
it
a
c
h
i
L
if
e
S
c
ie
n
c
e
,
S
a
it
a
m
a
,
J
a
p
a
n
)
7
2
(5
5
/1
8
)
2
2
(1
6
/6
)
3
6
.1
/3
8
.6
1
8
5
S
a
to
h
e
t
a
l1
5
T
c
e
lls
A
c
u
s
to
m
a
rr
a
y
w
it
h
1
2
5
8
c
D
N
A
s
(H
it
a
c
h
i
L
if
e
S
c
ie
n
c
e
,
S
a
it
a
m
a
,
J
a
p
a
n
)
7
2
(5
5
/1
8
)
2
2
(1
6
/6
)
3
6
.1
/3
8
.6
2
8
1
S
a
to
h
e
t
a
l1
6
P
B
M
C
,
p
e
ri
p
h
e
ra
l
b
lo
o
d
m
o
n
o
n
u
c
le
a
r
c
e
ll.
4 Kemppinen AK, Kaprio J, Palotie A, et al. BMJ Open 2011;1:e000053. doi:10.1136/bmjopen-2011-000053
Systematic review of genome-wide expression studies in multiple sclerosis
 group.bmj.com on January 10, 2013 - Published by bmjopen.bmj.comDownloaded from 
associated with PI3K signalling in B lymphocytes
(p¼1.3Ee06), and B cell development (p¼2.6Ee06)
pathways. In addition, altered T cell and B cell signalling
in rheumatoid arthritis, role of PKR in interferon
induction and antiviral response, and production of
nitric oxide and reactive oxygen species in macrophages
pathways showed evidence of association with the
differentially expressed genes (p<1Ee04).
Systematic review identifies 229 genes reported in at least
two studies
In order to perform a systematic review of expression
studies in MS, we identified eight previous studies, which
filled our selection criteria (table 1). Studies which had
been conducted in the same set of patients were
combined, and we therefore considered six previously
published independent lists of differentially expressed
genes. Together with our previously unpublished
experiment, these studies identified 2017 unique genes
with increased expression and 1860 with decreased
expression in MS, of which 303 genes were reported to
have both increased and decreased expression. However,
this list is not comprehensive, as two of the studies did
not provide full lists of the identified genes. Two
hundred and twenty-nine of the genes were found to
have differential expression in MS to the same direction
in at least two studies (supplementary table 2) and will
be referred to as ‘in silico replicated’ differentially
expressed genes (DEGs). One hundred and eleven of
these had increased expression, and 119 decreased
expression in MS, with one gene (STK4) identified as
both. Eleven of the 229 genes were differentially
expressed in three studies, and one gene, HSPA1A, in
four studies (table 2). We acknowledge that our
unpublished experiment may have been confounded by
technical differences in processing of the patient and
control samples, as well as by the age difference between
cases and controls. In addition, the study included four
patients who had received treatment, which may also
have had an impact on the results. After excluding
our study, 135 of the 229 DEGs were identified in at
least two independent studies. These are indicated in
supplementary table 2.
Several immunological pathways are significantly
associated with the in silico replicated DEGs
In order to explore whether the in silico replicated DEGs
are associated with specific pathways, we applied again
the canonical pathway analysis option in the Ingenuity
Pathway Analysis software. We conducted pathway anal-
ysis on the 135 DEGs identified in at least two indepen-
dent studies excluding our unpublished study, and on
the 229 DEGs identified when including our study.
Unsurprisingly, many of the 20 most significantly asso-
ciated pathways are related to immunological functions
(tables 3, 4), with the most significantly associated
pathway in both analyses being the glucocorticoid
receptor signalling pathway. Other top-rated pathways
include molecular mechanisms of cancer, NF-kB signal-
ling and several interleukin (IL) signalling pathways
(IL-4, IL-6, IL-17).
FIFTEEN IN SILICO REPLICATED DEGS ARE SUGGESTIVELY
ASSOCIATED WITH MS
We then investigated whether the 229 in silico replicated
DEGs showed any evidence for association in five previ-
ously published GWASs or in a recently published GWAS
meta-analysis after excluding single nucleotide poly-
morphisms (SNP) in the human leukocyte antigen
region (6p21e22).1e6 All association p values were avail-
able for the GWASs by Jakkula et al4 and International
Multiple Sclerosis Genetics Consortium (IMSGC),1 and
we therefore first examined the p value distribution of
SNPs mapping within 100 kb of the 229 DEGs by quan-
tileequantile plots. Interestingly, these SNPs showed an
overall enrichment of p values in the range 0.1e0.001 in
the IMSGC GWAS (figure 2). However, we did not see any
evidence of enrichment in the Finnish GWAS. We then
reviewed the reported SNPs in the five published GWASs
and the GWAS meta-analysis, and found 15 of the 229 in
Table 2 Genes identified as up- or down-regulated in multiple sclerosis in at least three studies
Gene Description
Direction of change in
expression in multiple sclerosis
ATP7A ATPase, Cu2+ transporting, alpha polypeptide Decreased (FIN11 15 16)
CCL3 Chemokine (C-C motif) ligand 3 Decreased11e13
CDKN1C Cyclin-dependent kinase inhibitor 1C (p57, Kip2) Decreased (FIN9 11)
HSPA1A Heat shock 70 kDa protein 1A Decreased9 12 13 15 16
PLAUR Plasminogen activator, urokinase receptor Decreased11e13
EIF4A1 Eukaryotic translation initiation factor 4A1 Increased (FIN9 11)
NEAT1 Nuclear paraspeckle assembly transcript 1 (non-protein coding) Increased (FIN9 11)
OGT O-linked N-acetylglucosamine (GlcNAc) transferase Increased (FIN11 12)
PTGS2 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H
synthase and cyclo-oxygenase)
Increased11e13
RBBP6 Retinoblastoma-binding protein 6 Increased (FIN9 11)
TNFAIP3 Tumour necrosis factor, alpha-induced protein 3 Increased (FIN11 15 16)
ZMYND8 Zinc finger, MYND-type containing 8 Increased (FIN11 12)
FIN, previously unpublished Finnish microarray screen described in detail here.
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silico replicated DEGs (including regions 100 kb up and
downstream) to contain suggestively associated SNPs
(p#0.0001) (table 5). The risk variants near three of the
genes, CDK4, IL7R and TNFRSF1A, have been confirmed
with genome-wide significance in GWASs or their follow-
up studies (p#53108).1 3 5 17
Table 3 Top 20 pathways associated with the 229 in silico replicated differentially expressed genes
Pathway
No of differentially expressed
genes in the pathway/total
no of genes in the pathway
Fisher exact
test p value
Glucocorticoid receptor signalling 30/250 2.1Ee16
IL-6 signalling 15/88 6.0Ee11
Hepatic fibrosis/hepatic stellate cell activation 16/116 3.6Ee10
Molecular mechanisms of cancer 24/303 1.8Ee09
IL-17 signalling 12/70 4.9Ee09
Pancreatic adenocarcinoma signalling 14/102 5.1Ee09
Nuclear factor (NF)-kb signalling 16/154 2.4Ee08
IL-10 signalling 11/65 2.5Ee08
Peroxisome Proliferator-Activated Receptor (PPAR) signalling 12/81 2.7Ee08
Role of osteoblasts, osteoclasts and chondrocytes in rheumatoid arthritis 17/189 7.5Ee08
Germ celleSertoli cell junction signalling 14/138 2.5Ee07
Dendritic cell maturation 14/139 2.7Ee07
Apoptosis signalling 11/86 4.9Ee07
p38 Mitogen-Activated Protein Kinase (MAPK) signalling 11/89 6.9Ee07
Colorectal cancer metastasis signalling 16/206 1.3Ee06
Atherosclerosis signalling 10/77 1.4Ee06
Tumor Necrosis Factor Receptor 1 (TNFR1) signalling 8/45 1.4Ee06
Regulation of IL-2 Expression in activated and anergic T lymphocytes 10/79 1.8Ee06
Peroxisome Proliferator-Activated Receptor Alpha (PPARa)/Retinoid X
Receptor Alpha (RXRa) activation
13/142 2.2Ee06
IL-4 signalling 9/64 2.4Ee06
IL, interleukin.
Table 4 Top 20 pathways associated with the 135 in silico replicated differentially expressed genes after excluding the Finnish
experiment
Pathway
No of differentially expressed
genes in the pathway/total
no of genes in the pathway
Fisher exact
test p value
Glucocorticoid receptor signalling 22/250 3.7Ee14
IL-17 signalling 9/70 7.0Ee08
Pancreatic adenocarcinoma signalling 10/102 1.8Ee07
IL-6 signalling 9/88 5.2Ee07
IL-2 signalling 7/52 1.5Ee06
Phosphatase and Tensin Homolog (PTEN) signalling 9/101 1.7Ee06
IL-15 signalling 7/60 4.1Ee06
Agrin interactions at neuromuscular junction 7/60 4.1Ee06
Tumor Necrosis Factor Receptor 1 (TNFR1) signalling 6/45 9.4Ee06
p21-Activated Protein Kinase (PAK) signalling 7/75 1.9Ee05
Phosphoinositide 3-Kinase (PI3K)/AKT signalling 8/108 2.5Ee05
Regulation of IL-2 expression in activated and anergic T lymphocytes 7/79 2.6Ee05
Molecular mechanisms of cancer 13/303 3.0Ee05
PPAR signalling 7/81 3.1Ee05
Aryl hydrocarbon receptor signalling 8/115 4.0Ee05
Role of Janus Kinase 1 (JAK1) and Januse Kinase 3 (JAK3) in gc
cytokine signalling
6/59 4.6Ee05
Nuclear factor (NF)-kb signalling 9/154 5.2Ee05
Stress-Activated Protein Kinase (SAPK)/c-Jun N-terminal Kinase
(JNK) signalling
7/90 6.1Ee05
Renal cell carcinoma signalling 6/64 7.3Ee05
IL-4 signalling 6/64 7.3Ee05
IL, interleukin.
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Suggestively associated variant correlates with CXCR4
expression
To address the question, whether the above identified
suggestively associated SNPs (p#0.0001) mapping to
15 in silico replicated DEGs might contribute to
the differential expression of these genes in MS, we
first examined the genes using the mRNA by SNP Browser
(http://www.sph.umich.edu/csg/liang/asthma/),18 19
which is a database of expression QTL (eQTL) SNP
variants. However, none of the suggestively associated
SNPs or their tagging SNPs (r2>0.8) correlated signifi-
cantly with the expression of the corresponding DEG
(p#0.001). We also investigated the expression of these
genes in risk allele carriers versus non-carriers in
lymphoblastoid cell lines of 60 Centre d’E´tude du Poly-
morphisme Humain (CEPH)-derived HapMap samples
(CEU) (GEO dataset GSE5859)20 and obtained geno-
types for the most strongly associated SNP, or SNPs if
identified in several GWASs, from HapMap Release 24
(http://www.hapmap.org).21 In CXCR4, we tested
rs882300, which was the most strongly associated CXCR4
SNP in a meta-analysis, instead of the two SNPs mapping
within 100 kb of the gene. We did not identify any
significant differences in expression between risk allele
carriers and non-carriers after correcting for multiple
testing. However, we found suggestive evidence for
a higher expression of CXCR4 in carriers of the associated
G allele at rs882300 (uncorrected one-sided p value¼0.04,
fold change¼1.36) (figure 3), which is in concordance
with the higher expression of CXCR4 observed in MS in
our Finnish microarray study and three other studies,
including two which were excluded from the systematic
review owing to small sample sizes.11 22 23 This effect was
also seen with the same probe set (217028_at) in our
microarray data in a combined sample of 11 MS patients
and 14 controls for which a genotype was available
(fold change 1.19, one-sided ManneWhitney test
p value¼0.06). However, no significant difference in
expression levels was observed in two other probe sets
measuring for the expression of CXCR4 in our microarray
data. Both of these probe sets recognize exonic
sequences, while 217028_at identifies 39UTR in CXCR4.
DISCUSSION
Despite extensive research and recent successes in
identifying genetic risk variants predisposing to MS, the
underlying molecular mechanisms still remain poorly
understood. Given the suggested role of autoimmunity
and predominance of immunological genes in loci
associated with MS, genome-wide expression profiling in
immune cells is a valid approach for further elucidating
genes and pathways involved in the disease pathogenesis.
Although several microarray experiments in MS have
been conducted, and a large number of differentially
expressed genes have been reported, in most cases the
samples have been small, and replication has been
lacking, making the findings difficult to interpret. While
no obvious consistencies have emerged from these
studies, there have not been any systematic attempts to
evaluate the overlap between them. We therefore
conducted a systematic review of seven microarray
studies including our previously unpublished study and
confirmed that the general overlap between the studies
was indeed poor: only 229 of all 3574 (6%) genes
reported to be differentially expressed in MS had been
identified in at least two studies, and 94% were therefore
unique to a single study. Only 12 of the 229 DEGs were
identified in at least three studies. These include NEAT1,
which encodes for a non-coding RNA and suppresses the
expression of CIITA, an activator of genes within the
major histocompatibility complex (MHC) class II
locus.24 Interestingly, the most frequently reported gene,
HSPA1A, which showed decreased expression in MS in
four studies, is also functionally connected to the MHC:
it encodes for a heat shock protein, which is likely to be
involved in MHC class I and II mediated antigen
presentation.25 The gene itself is located in the MHC
class III region next to a highly homologous HSPA1B
gene, and the measured expression levels may reflect the
expression of both genes.
However, as is the case for expression studies in
general, the studies are not directly comparable owing to
differences in samples, sample sizes and platforms, as
well as in criteria used for data quality control and for
declaring differential expression. Furthermore, the
majority of all reported genes came from the only two
studies conducted in whole blood samples, and it is
therefore not necessarily surprising that most of these
genes were not identified in studies conducted in PBMCs
or lymphocyte populations. Two studies also reported
only a subset of the identified genes, and some studies
were conducted using microarrays covering only a frac-
tion of currently known human genes. However, perhaps
the most likely explanation for poor overlap across
Figure 2 Quantileequantile plot for
CochraneManteleHaenszel p values in the International
Multiple Sclerosis Genetics Consortium genome-wide
association studies highlighting single nucleotide
polymorphisms (SNP) in genes showing differential expression
in multiple sclerosis. SNPs in 6p21e22 were excluded. Red
dots represent SNPs mapping within 100 kb of in silico
replicated differentially expressed genes. The remaining SNPs
are represented by black dots. Plot A shows the entire p value
distribution, and plot B is a close-up showing the enrichment of
observed p values in the range 0.1e0.001.
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studies is a high rate of false positives and low power to
detect true differences in small samples. Recent GWASs
conducted in large samples have proven that most of the
early genetic associations reported in candidate gene
studies of at most a few hundred individuals seem to
have been false positives. Small samples may be even
more problematic in expression studies, which are
susceptible to noise introduced by technical and bio-
logical factors. Large studies are required, especially if
the aim is to identify expression changes which are due
to genetic disease risk variants because the effects of
common genetic variants on gene expression are in most
cases relatively modest, even in rather homogeneous cell
populations,26 and in small samples the difference in
risk allele frequency between cases and controls is not
expected to be significant in the first place.
However, after excluding 13 genes in the MHC region,
the 229 in silico replicated DEGs were enriched for
variants showing a modest association in the IMSGC
GWAS,1 suggesting that at least some of these genes are
likely to play a causative role in MS rather than showing
Table 5 Non-human leukocyte antigen single nucleotide polymorphisms (SNP) in silico replicated differentially expressed
genes with p#0.0001 in a genome-wide association study
Gene SNP
Chr:bp position
(hg18) p Value
Genome-wide
association study
Direction of change in
expression in multiple
sclerosis
ANXA1 rs13292677 9:74870791 0.0001 Baranzini et al2 Increased9 11
rs1961830 9:74872500 0.0001
rs7863238 9:74886984 0.0001
rs1342022 9:74895327 0.0001
rs2310333 9:74897200 0.0001
CD40 rs6131010 20:44157712 8.5Ee07 ANZgene5 Increased (FIN11)
rs6074022 20:44173603 1.3Ee07
rs1569723 20:44175471 2.9Ee07
rs3746821 20:44188518 9.7Ee05 IMSGC1
rs2425764 20:44233852 2.5Ee05
CDK4 rs10876994 12:56351004 5.4Ee11 ANZgene5 Decreased11 15 16
rs12368653 12:56419523 2.7Ee10
rs703842 12:56449006 1.0Ee07
CXCR4 rs4954555 2:136509584 0.0001 Baranzini et al2 Increased (FIN11)
rs7574456 2:136606529 2.5Ee05 De Jager et al3
rs1519529 2:136690727 4.1Ee05
C7orf54 rs1193335 7:127404040 3.0Ee05 De Jager et al3 Increased (FIN9)
GNG2 rs4468527 14:51394881 4.1Ee05 De Jager et al3 Decreased9 16
IL7R rs931555 5:35839334 2.7Ee06 De Jager et al3 Increased12 14
rs6897932 5:35910332 1.7Ee06
ITPR1 rs711663 3:4437774 1.6Ee05 De Jager et al3 Increased (FIN11)
NPEPPS rs9901869 17:42930205 2.9Ee06 De Jager et al3 Increased11 12
rs4239162 17:43110809 6.9Ee06
rs11079784 17:43057279 3.6Ee05 Baranzini et al2
PAK2 rs6583176 3:198009975 3.9Ee05 De Jager et al3 Decreased9 15 16
TGFBR2 rs12490899 3:30649258 5.7Ee05 De Jager et al3 Decreased9 15 16
TNFAIP3 rs892999 6:138180398 3.1Ee06 De Jager et al3 Increased (FIN11 15 16)
TNFRSF1A rs1800693 12:6310270 1.6Ee11 De Jager et al3 Decreased (FIN15 16)
rs4149576 12:6319376 1.0Ee08
TRIB2 rs7607490 2:12768571 1.0Ee05 Baranzini et al2 Increased11 12
ZMIZ1 rs1250540 10:80706013 1.6Ee06 De Jager et al3 Decreased9 11
The best p value is shown if several p values were provided.
FIN, previously unpublished Finnish microarray screen described in detail here.
Figure 3 Box plot of CXCR4 expression and rs882300
genotype in 60 Centre d’E´tude du Polymorphisme Humain
(CEPH) lymphoblastoid cell samples.
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differential expression as a result of activation of
immunological pathways secondary to MS. In addition,
15 of these genes have shown suggestive evidence for
association with MS (p<0.0001) including CDK4, IL7R
and TNFRSF1A, which are located in regions of genome-
wide significance.1 3 5 17 These 15 also include CD40,
which is associated with rheumatoid arthritis,27 and
TNFAIP3, which is associated with coeliac disease, SLE,
psoriasis and rheumatoid arthritis.28e31 TNFAIP3 was
also one of the genes identified as differentially
expressed in three studies, including our own experi-
ment.11 15 16 It encodes for a zinc finger protein which
inhibits nuclear factor (NF)-kb activity and tumour
necrosis factor (TNF)-mediated programmed cell death,
and may therefore play an important role in regulating
various immunological pathways.32 However, apart from
CXCR4, the expression of the 15 DEGs did not correlate
with the proposed risk variants in lymphoblastoid cell
lines, although potential eQTL effects should be further
investigated in other immune cells populations. In
CXCR4, the associated SNP correlated modestly with
expression when measured by a probe set representing
the 39UTR, which may indicate differential usage of
alternative polyadenylation signals. Interestingly, CXCR4
promotes transendothelial migration of T cells in vitro
together with its ligand, CXCL12,33 while CXCR4 and
CXCR3 antagonists reduce the accumulation of CD4+ T
cells in the CNS and inhibit EAE pathogenesis.34
We acknowledge that results from our previously
unpublished experiment may have been affected by
technical factors as well as by the age difference between
cases and controls. The study also included four patients
who had received treatment. We therefore reviewed the
list of DEGs after excluding our study and found that
135 of the 229 DEGs were identified in at least two
independent studies. Pathway analysis on both the 229
and 135 in silico replicated DEGs showed that they were
highly associated with several immunological pathways.
Interestingly, the identified interleukin signalling path-
ways (IL-4, IL-6 and IL-17) are primarily related to Th2
and Th17 cells rather than Th1 cells, which are thought
to mediate MS.35e37 Further, IL-6 regulates the balance
between regulatory T cell and Th17 cell differentiation
together with TGF-b.38 Th17 cells have been linked with
autoimmunity, and several studies have provided
evidence for their role in MS and EAE,39 while regula-
tory T cells have been demonstrated to display loss of
suppressive function in MS.40 Further studies are needed
to investigate whether changes in expression of genes in
these interleukin signalling pathways are causative or
secondary to MS. We also saw a strong association with
cancer-related pathways, which may suggest some
common molecular mechanisms behind cancer and
autoimmunity, such as dysregulation of apoptosis
signalling. Finally, the pathway showing most significant
association with the in silico replicated DEGs was the
glucocorticoid receptor signalling pathway, which is
a central regulator of inflammation. Although one could
speculate that this may reflect the usage of corticoste-
roids as a treatment for MS, patients in the included
studies had reportedly been untreated shortly prior to
sample collection apart from our study where two
patients had been treated with cortisone. This pathway
was also the most significantly associated when our study,
which included treated patients, was excluded. This
would suggest that the regulation of endogenous
glucocorticoid receptor signalling pathway may be
disturbed in MS, which is in concordance with previous
evidence of reduced glucocorticoid receptor binding
affinity and sensitivity in lymphocytes in MS patients.41 42
Furthermore, mice producing an antisense RNA for the
glucocorticoid receptor do not develop EAE.43 Interest-
ingly, several of the genes in confirmed MS risk loci are
connected to the glucocorticoid receptor signalling
pathway, including STAT3, which was recently identified
through a GWAS by our group4 and acts as a co-activator
of glucocorticoid receptor signalling.44
In conclusion, we have performed the first systematic
review of microarray studies in MS. In general, there was
little overlap between the seven studies investigated,
most likely owing to the small sizes of these studies.
However, 229 genes were reported to be differentially
expressed in MS in at least two studies. After excluding
our unpublished experiment, which may have been
affected by confounding factors and inclusion of treated
subjects, 135 genes were identified in at least two studies.
Of the 229 genes, 12 were reported in at least three
studies, including TNFAIP3, which is associated with
several other autoimmune diseases, and NEAT1 and
HSPA1A, which are both functionally connected to
MHC, the major MS susceptibility locus. Pathway anal-
yses on the 229 and 135 DEGs provided support for the
involvement of glucocorticoid receptor signalling and
Th2, Th17 and regulatory T-cell-related interleukin
signalling pathways in MS. Together with accumulating
data from genetic association studies, our findings can
be helpful in selecting genes and pathways for further
functional studies in MS.
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